文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

经 BNT162b2 加强针免疫后整合免疫参数识别出功能性 CVIDs 表型聚类。

Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters.

机构信息

B Cell Unit, Immunology Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

出版信息

Front Immunol. 2023 May 25;14:1194225. doi: 10.3389/fimmu.2023.1194225. eCollection 2023.


DOI:10.3389/fimmu.2023.1194225
PMID:37304298
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10248522/
Abstract

INTRODUCTION: Assessing the response to vaccinations is one of the diagnostic criteria for Common Variable Immune Deficiencies (CVIDs). Vaccination against SARS-CoV-2 offered the unique opportunity to analyze the immune response to a novel antigen. We identify four CVIDs phenotype clusters by the integration of immune parameters after BTN162b2 boosters. METHODS: We performed a longitudinal study on 47 CVIDs patients who received the 3rd and 4th vaccine dose of the BNT162b2 vaccine measuring the generation of immunological memory. We analyzed specific and neutralizing antibodies, spike-specific memory B cells, and functional T cells. RESULTS: We found that, depending on the readout of vaccine efficacy, the frequency of responders changes. Although 63.8% of the patients have specific antibodies in the serum, only 30% have high-affinity specific memory B cells and generate recall responses. DISCUSSION: Thanks to the integration of our data, we identified four functional groups of CVIDs patients with different B cell phenotypes, T cell functions, and clinical diseases. The presence of antibodies alone is not sufficient to demonstrate the establishment of immune memory and the measurement of the in-vivo response to vaccination distinguishes patients with different immunological defects and clinical diseases.

摘要

简介:评估疫苗接种反应是常见可变免疫缺陷(CVIDs)的诊断标准之一。接种 SARS-CoV-2 疫苗提供了分析新型抗原免疫反应的独特机会。我们通过整合 BTN162b2 加强针后的免疫参数,确定了四种 CVIDs 表型簇。

方法:我们对 47 名接受 BNT162b2 疫苗第 3 剂和第 4 剂疫苗接种的 CVIDs 患者进行了纵向研究,测量免疫记忆的产生。我们分析了特异性和中和抗体、刺突特异性记忆 B 细胞和功能性 T 细胞。

结果:我们发现,根据疫苗疗效的检测结果,应答者的频率发生变化。尽管 63.8%的患者血清中存在特异性抗体,但只有 30%的患者具有高亲和力的特异性记忆 B 细胞,并产生回忆反应。

讨论:由于我们的数据整合,我们确定了具有不同 B 细胞表型、T 细胞功能和临床疾病的 CVIDs 患者的四个功能组。仅存在抗体不足以证明免疫记忆的建立,并且对疫苗接种体内反应的测量可区分具有不同免疫缺陷和临床疾病的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/af599c2471c2/fimmu-14-1194225-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/2ff3a0fd0ce6/fimmu-14-1194225-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/e43952a5e69d/fimmu-14-1194225-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/a9ac1e8f1206/fimmu-14-1194225-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/e517d6c492ef/fimmu-14-1194225-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/e2bbf7c10d43/fimmu-14-1194225-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/6c0659a9c33c/fimmu-14-1194225-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/bf02a0f51505/fimmu-14-1194225-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/5479cd1a5758/fimmu-14-1194225-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/af599c2471c2/fimmu-14-1194225-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/2ff3a0fd0ce6/fimmu-14-1194225-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/e43952a5e69d/fimmu-14-1194225-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/a9ac1e8f1206/fimmu-14-1194225-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/e517d6c492ef/fimmu-14-1194225-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/e2bbf7c10d43/fimmu-14-1194225-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/6c0659a9c33c/fimmu-14-1194225-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/bf02a0f51505/fimmu-14-1194225-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/5479cd1a5758/fimmu-14-1194225-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56ed/10248522/af599c2471c2/fimmu-14-1194225-g009.jpg

相似文献

[1]
Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters.

Front Immunol. 2023

[2]
Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders.

J Allergy Clin Immunol. 2023-4

[3]
Antigen-Specific CD4 T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination.

Front Immunol. 2022

[4]
B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.

Cells. 2021-10-27

[5]
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters.

J Med Virol. 2023-1

[6]
T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies.

Cells. 2022-6-14

[7]
Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered.

Front Immunol. 2023

[8]
Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.

Front Immunol. 2022

[9]
Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.

BMC Med. 2022-6-9

[10]
Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.

Hum Vaccin Immunother. 2023-12-31

引用本文的文献

[1]
T and B cell responses in different immunization scenarios for COVID-19: a narrative review.

Front Immunol. 2025-3-18

[2]
Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.

Front Immunol. 2025-3-6

[3]
Impairment of Innate Immunity and Depletion of Vaccine-Induced Memory B and T Cells in the Absence of the Spleen.

Am J Hematol. 2025-5

[4]
An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity.

Vaccines (Basel). 2024-6-18

[5]
Impact of Exposure to Vaccination and Infection on Cellular and Antibody Response to SARS-CoV-2 in CVID Patients Through COVID-19 Pandemic.

J Clin Immunol. 2023-12-22

[6]
SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience.

Front Immunol. 2023

本文引用的文献

[1]
Cellular and humoral immunogenicity of the COVID-19 vaccine and COVID-19 disease severity in individuals with immunodeficiency.

Front Immunol. 2023

[2]
Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine.

N Engl J Med. 2023-3-2

[3]
COVID-19 and Inborn Errors of Immunity.

Physiology (Bethesda). 2022-11-1

[4]
IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2.

J Exp Med. 2022-9-5

[5]
T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies.

Cells. 2022-6-14

[6]
Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines.

Immunol Rev. 2022-9

[7]
CD21 CD27 Atypical B Cells in a Pediatric Cohort Study: An Extensive Single Center Flow Cytometric Analysis.

Front Pediatr. 2022-6-3

[8]
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost.

Nature. 2022-7

[9]
Immunogenicity of a third COVID-19 messenger RNA vaccine dose in primary immunodeficiency disorder patients with functional B-cell defects.

J Allergy Clin Immunol Pract. 2022-5

[10]
Antigen-Specific CD4 T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination.

Front Immunol. 2022

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索